Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Intellia Thera CS (NTLA)

Intellia Thera CS (NTLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Tue Dec 3, 3:01PM CST

NTLA : 12.18 (+0.83%)
Intellia Therapeutics Announces FDA Grants RMAT Designation for CRISPR-Based Therapy nexiguran ziclumeran in Treating Hereditary ATTR Amyloidosis Quiver Quantitative, Inc. - Mon Nov 25, 4:48PM CST

Intellia Therapeutics receives FDA RMAT designation for nexiguran ziclumeran, a CRISPR therapy for hereditary ATTR amyloidosis.Quiver AI SummaryIntellia Therapeutics, Inc. announced that the U.S. FDA has...

NTLA : 12.18 (+0.83%)
Fearless girl in front of bull on Wall Street by Daniel Lloyd Blunk-Fernandez via Unsplash
2 Penny Stocks That Wall Street Predicts Will Soar 306% to 1,183% in 2025 Barchart - Mon Nov 25, 9:00AM CST

Both penny stocks are a 'strong buy' on Wall Street.

CABA : 2.38 (+3.03%)
$SPX : 5,930.85 (+1.09%)
NTLA : 12.18 (+0.83%)
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy GlobeNewswire - Mon Nov 25, 6:30AM CST

NTLA : 12.18 (+0.83%)
Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock? Motley Fool - Fri Nov 22, 7:30AM CST

Shares of biotech Intellia Therapeutics (NASDAQ: NTLA) are down by around 33% over the past 30 days, amid the publication of some new data from an early stage clinical trial on Nov. 16 and its third-quarter...

NTLA : 12.18 (+0.83%)
Intellia Therapeutics Reports Promising Phase 1 Trial Results for Nexiguran Ziclumeran in ATTR Amyloidosis Quiver Quantitative, Inc. - Sat Nov 16, 7:28PM CST

Intellia Therapeutics announces positive Phase 1 trial results for nex-z in ATTR amyloidosis, indicating significant TTR reduction and disease stabilization.Quiver AI SummaryIntellia Therapeutics announced...

NTLA : 12.18 (+0.83%)
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis GlobeNewswire - Sat Nov 16, 9:16AM CST

NTLA : 12.18 (+0.83%)
Author
3 Fast-Growing Stocks Analysts See Doubling in Price MarketBeat - Mon Nov 11, 6:14AM CST

Clinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches.

IMCR : 28.33 (-0.33%)
GHRS : 6.85 (-7.31%)
NTLA : 12.18 (+0.83%)
Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress GlobeNewswire - Thu Nov 7, 6:30AM CST

NTLA : 12.18 (+0.83%)
Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day? Motley Fool - Wed Nov 6, 8:45AM CST

There's nothing bearish at all about what it reported recently.

NTLA : 12.18 (+0.83%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot